In some cancers, such as B-acute lymphoblastic leukaemia and Acute Myeloid Leukemia, IGJ expression was found to be correlated with prognosis24,25 and in hepatocellular carcinoma a high expression of IGJ together with CD5 antigen-like (CD5L) and galectin-3-binding protein (LGALS3BP) was reported to predict response to the chemotherapeutic agent Sorafenib26. The gene discussed is LGALS3BP; the disease is acute myeloid leukemia.